文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

miR-33a-5p/CROT 轴介导卵巢癌细胞行为和化疗耐药与 TGF-β 信号通路的调节。

The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance the regulation of the TGF-β signal pathway.

机构信息

Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Front Endocrinol (Lausanne). 2022 Sep 2;13:950345. doi: 10.3389/fendo.2022.950345. eCollection 2022.


DOI:10.3389/fendo.2022.950345
PMID:36120434
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9478117/
Abstract

Due to the lack of symptoms and detection biomarkers at the early stage, most patients with ovarian cancer (OC) are diagnosed at an advanced stage and often face chemoresistance and relapse. Hence, defining detection biomarkers and mechanisms of chemoresistance is imperative. A previous report of a cDNA microarray analysis shows a potential association of carnitine O-octanoyltransferase (CROT) with taxane resistance but the biological function of CROT in OC remains unknown. The current study explored the function and regulatory mechanism of CROT on cellular behavior and paclitaxel (PTX)-resistance in OC. We found that CROT was downregulated in OC tissues and PTX-resistant cells. Furthermore, CROT expression was negatively correlated with the prognosis of OC patients. Overexpression of CROT inhibited the OC cell proliferation, migration, invasion, and colony formation, arrested the cell cycle at the G2/M phase, and promoted cell apoptosis. In addition, miR-33a-5p bound directly to the 3'UTR of CROT to negatively regulate the expression of CROT and promoted OC cell growth. Finally, overexpression of CROT decreased the phosphorylation of Smad2, whereas knockdown of CROT increased the nuclear translocation of Smad2 and Smad4, two transducer proteins of TGF-β signaling, indicating that CROT is a tumor suppressor which mediates OC cell behaviors through the TGF-β signaling pathway. Thus, targeting the miR-33a-5p/CROT axis may have clinical potential for the treatment of patients with OC.

摘要

由于在早期缺乏症状和检测生物标志物,大多数卵巢癌(OC)患者在晚期被诊断出来,并且经常面临化疗耐药和复发。因此,确定检测生物标志物和化疗耐药的机制至关重要。先前的 cDNA 微阵列分析报告显示肉毒碱 O-辛酰基转移酶(CROT)与紫杉烷耐药之间存在潜在关联,但 CROT 在 OC 中的生物学功能尚不清楚。本研究探讨了 CROT 对 OC 细胞行为和紫杉醇(PTX)耐药性的功能和调控机制。我们发现 CROT 在 OC 组织和 PTX 耐药细胞中表达下调。此外,CROT 表达与 OC 患者的预后呈负相关。CROT 的过表达抑制 OC 细胞的增殖、迁移、侵袭和集落形成,将细胞周期阻滞在 G2/M 期,并促进细胞凋亡。此外,miR-33a-5p 直接结合 CROT 的 3'UTR 以负调控 CROT 的表达,并促进 OC 细胞生长。最后,CROT 的过表达降低了 Smad2 的磷酸化,而 CROT 的敲低增加了 TGF-β信号通路的转导蛋白 Smad2 和 Smad4 的核易位,表明 CROT 是一种肿瘤抑制因子,通过 TGF-β信号通路介导 OC 细胞行为。因此,靶向 miR-33a-5p/CROT 轴可能具有治疗 OC 患者的临床潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/50dd7c936e1d/fendo-13-950345-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/4682a19f76be/fendo-13-950345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/081dcd381004/fendo-13-950345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/e29f9916215a/fendo-13-950345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/67239ca8be43/fendo-13-950345-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/ebd3d56cfb40/fendo-13-950345-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/d262607e2558/fendo-13-950345-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/7cbfea753b0a/fendo-13-950345-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/50dd7c936e1d/fendo-13-950345-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/4682a19f76be/fendo-13-950345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/081dcd381004/fendo-13-950345-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/e29f9916215a/fendo-13-950345-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/67239ca8be43/fendo-13-950345-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/ebd3d56cfb40/fendo-13-950345-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/d262607e2558/fendo-13-950345-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/7cbfea753b0a/fendo-13-950345-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d458/9478117/50dd7c936e1d/fendo-13-950345-g008.jpg

相似文献

[1]
The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance the regulation of the TGF-β signal pathway.

Front Endocrinol (Lausanne). 2022

[2]
A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.

Oncogene. 2021-7

[3]
CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.

Drug Dev Res. 2022-4

[4]
Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.

Eur Rev Med Pharmacol Sci. 2020-1

[5]
Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.

Biosci Rep. 2020-4-30

[6]
Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.

Sci Rep. 2021-1-12

[7]
MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.

Cancer Gene Ther. 2022-6

[8]
Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.

Am J Physiol Cell Physiol. 2018-5-2

[9]
UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.

Biochem Biophys Res Commun. 2018-5-19

[10]
F-Box and Leucine-Rich Repeat Protein 20 (FBXL20), Negatively Regulated by microRNA (miR)-195-5p, Accelerates the Malignant Progression of Ovarian Cancer.

Mol Biotechnol. 2021-12

引用本文的文献

[1]
Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.

J Ovarian Res. 2025-8-14

[2]
Drug resistance in ovarian cancer: from mechanism to clinical trial.

Mol Cancer. 2024-3-28

[3]
SMAD4 inhibits glycolysis in ovarian cancer through PI3K/AKT/HK2 signaling pathway by activating ARHGAP10.

Cancer Rep (Hoboken). 2024-1-17

[4]
Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.

J Cancer. 2023-8-15

[5]
"DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.

Front Oncol. 2023-6-28

[6]
MCF2L-AS1 promotes the biological behaviors of hepatocellular carcinoma cells by regulating the miR-33a-5p/FGF2 axis.

Aging (Albany NY). 2023-7-10

本文引用的文献

[1]
Lipid-coated albumin-paclitaxel nanoparticles loaded with sorcin-siRNA reverse cancer chemoresistance via restoring intracellular calcium ion homeostasis.

J Nanobiotechnology. 2022-7-7

[2]
Phenotypic plasticity during metastatic colonization.

Trends Cell Biol. 2022-10

[3]
Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFβ1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma.

Int J Biol Sci. 2022

[4]
Cancer statistics, 2022.

CA Cancer J Clin. 2022-1

[5]
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments.

Semin Cancer Biol. 2021-12

[6]
Tumour fatty acid metabolism in the context of therapy resistance and obesity.

Nat Rev Cancer. 2021-12

[7]
A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.

Oncogene. 2021-7

[8]
Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020.

Chin Med J (Engl). 2021-3-17

[9]
TGFβ signaling networks in ovarian cancer progression and plasticity.

Clin Exp Metastasis. 2021-4

[10]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

CA Cancer J Clin. 2021-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索